{"retracted":false,"update":{"timestamp":1489968000000,"doi":"10.1080/09546634.2017.1307464","type":"correction"},"doi":"10.1080/09546634.2017.1294727","journal":"Journal of Dermatological Treatment","publisher":"Informa UK Limited","title":"Correction to: Psoriasis patients with psoriasis Area and Severity Index (PASI) 90 response achieve greater health-related quality-of-life improvements than those with PASI 75â€“89 response: results from two phase 3 studies of secukinumab"}
